Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

SHIELD THERAPEUTICS PLC

(STX)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur SHIELD THERAPEUTICS PLC
08/10SHIELD THERAPEUTICS : Licence agreement secured in Republic of Korea for Accrufer
07/10SHIELD THERAPEUTICS : Licence agreement secured in Republic of Korea for Accrufer®
27/09FTSE 100 Rises, Supply Constraints Could Hit Pound
27/09SHIELD THERAPEUTICS : Names New Chief Medical Officer
27/09SHIELD THERAPEUTICS : Jose A. Menoyo MD Appointed as Chief Medical Officer
27/09FTSE Rises as Oil Stocks Gain Due to Higher Crude Prices
27/09Shield Therapeutics plc Announces Management Changes
17/08FTSE 100 Rises 0.4% on BHP News
17/08FTSE 100 Flat as Delta Variant Fears Weigh
17/08SHIELD THERAPEUTICS : Interim Report for the six months ended 30 June 2021
17/08Sterling Falls as Traders React to Jobs Data
17/08Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2021
12/08Shield Therapeutics plc Enters into an Exclusive Licence Agreement for Accrufer with Ko..
09/08Shield Therapeutics plc Notes Publication of Aegis-Ckd Study Results in Ajkd
24/06SHIELD THERAPEUTICS : US launch of Accrufer® confirmed for July 1, 2021
24/06Shield Therapeutics plc Confirms to Launch Accrufer® in the US on July 1, 2021
18/06SHIELD THERAPEUTICS' : New CEO Assumes Position
28/05SHIELD THERAPEUTICS : Appointment of new Chief Executive Officer
28/05SHIELD THERAPEUTICS : to Appoint New CEO in June; Shares Up 5%
28/05Shield Therapeutics plc Announces Executive Changes, Effective June 1, 2021
28/05Shield Therapeutics plc Announces Board Changes
26/05SHIELD THERAPEUTICS : Accrufer Launch on Schedule
24/05SHIELD THERAPEUTICS : confirms it remains on track to launch Accrufer® in the US by end of..
21/05Shield Therapeutics plc Confirms It Remains on Track to Launch Accrufer® in the US by E..
21/05SHIELD THERAPEUTICS : confirms it remains on track to launch Accrufer® in the US by end of..
18/05SHIELD THERAPEUTICS : AEGIS-H2H study results published in Inflammatory Bowel Diseases
18/05Shield Therapeutics plc Announces Study Results in Inflammatory Bowel Diseases
18/05SHIELD THERAPEUTICS : Starts Trading On OTCQX In US
13/05SHIELD THERAPEUTICS : 2020 Annual Report and 2021 AGM Notice
13/05SHIELD THERAPEUTICS : Notice of Annual General Meeting (“AGM”) 2021
13/05Shield Therapeutics plc Auditor Raises 'Going Concern' Doubt
10/05SHIELD THERAPEUTICS : Appointment of Two Non-Executive Directors
10/05Shield Therapeutics plc Announces Board Changes
29/04SHIELD THERAPEUTICS : Results for the Year Ended 31 December 2021 - Investor Presentation
29/04SHIELD THERAPEUTICS : Preliminary results for the Year Ended 31 December 2020
29/04Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2..
09/04SHIELD THERAPEUTICS : Proactive Investor 1-2-1 Forum
26/03Shield Therapeutics plc Announces Study Demonstrates Effectiveness of Ferric Maltol
25/03SHIELD THERAPEUTICS : Shares Magazine/AJ Bell Webinar
25/03SHIELD THERAPEUTICS : IMC Presentation
22/03SHIELD THERAPEUTICS : Names CFO
22/03Shield Therapeutics plc Appoints Hans-Peter Rudolf as Chief Financial Officer
18/03SHIELD THERAPEUTICS : Result of General Meeting & Open Offer
09/03Shield Therapeutics plc Announces Australia's Therapeutic Goods Administration Approves..
09/03SHIELD THERAPEUTICS : Australia's Therapeutic Goods Administration (TGA) approves Feraccru..
01/03INTUITIVE INVESTMENTS : Acquires Nearly 1 Million Shares In Shield Therapeutics
01/03SHIELD THERAPEUTICS : Shareholder Placing/Subscription Circular and Notice of GM
01/03SHIELD THERAPEUTICS : Shareholder Placing/Subscription Circular - Notice of GM
26/02SHIELD THERAPEUTICS : Successful completion of £25 million Fundraise
26/02SHIELD THERAPEUTICS : Placing and Subscription to raise up to £25 million, Open Offer to r..
18/01SHIELD THERAPEUTICS : Business and trading update
15/01SHIELD THERAPEUTICS' : Projected FY20 Revenue Boosted by Payment for License Agreement
15/01Shield Therapeutics plc Provides Revenue Guidance for the Year 2020
2020SHIELD THERAPEUTICS : Investor Meet Presentation
2020SHIELD THERAPEUTICS : considering launch of Accrufer in the USA, Loan facilities agreed
2020SHIELD THERAPEUTICS : considering launch of Accrufer® in the USA – Loan facilities a..
2020Shield Therapeutics plc Provides an Update on Its Plans to Commercialise Accrufer® in t..
2020SHIELD THERAPEUTICS : Peer Teva Pharmaceutical Industries Withdraws Oppositions to Patents
2020SHIELD THERAPEUTICS : Interim Results 2020
2020SHIELD THERAPEUTICS : Half-year Report Interim Report for the six months ended 30 June 202..
2020Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2020
2020SHIELD THERAPEUTICS : Shield provides the headline results from the reanalysis of the AEGI..
2020Shield Therapeutics plc Appoints Christian Schweiger as Non-Executive Director
2020SHIELD THERAPEUTICS : Results of 2020 Annual General Meeting
2020SHIELD THERAPEUTICS : Feraccru®/Accrufer® publications
2020Shield Therapeutics plc Notes the Publication of Two Papers Concerning Feraccru®/Accruf..
2020SHIELD THERAPEUTICS : Investor presentations
2020SHIELD THERAPEUTICS : Appointment of Chairman
2020Shield Therapeutics plc Announces Management Changes
2020SHIELD THERAPEUTICS : 2019 Annual Report and 2020 AGM Notice
2020SHIELD THERAPEUTICS : Preliminary Results for the Year Ended 31 December 2019
2020Shield Therapeutics plc Auditor Raises 'Going Concern' Doubt
2020James Karis Steps Down from the Board At Shield Therapeutics plc
2020Shield Therapeutics plc Provides Operational Updates
2020Shield Therapeutics plc Announces Exclusive Licence Agreement with Beijing Aosaikang Ph..
1  2  3Suiv.
Prochain événement sur SHIELD THERAPEUTICS PLC